Michael A.ThompsonMDPhD, FASCO

Oncology • Summit, WI

Hematologic Oncology

Vice President of Clinical Partnerships, Tempus Labs

Join to view full profile

Dr. Thompson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thompson's full profile

Already have an account?

Office
36500 Aurora Dr
Summit, WI 53066
Phone+1 262-434-8800

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 2001 - 2002
Mayo Graduate School (MD/PhD Program)PhD, Molecular Pharmacology & Experimental Therapeutics, 1993 - 2001
Mayo Clinic College of MedicineClass of 2001
University of Wisconsin at MadisonBS, Molecular Biology, Honors, 1989 - 1993

Certifications & Licensure

WI State Medical License 2007 - 2025
TX State Medical License 2004 - 2014
MN State Medical License 2002 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

Clinical Trials Research Award Aurora Research Institute, 2014
"Man of the Year" Nominee, SE Wisconsin Leukemia & Lymphoma Society (LLS), 2012
ASCO Leadership Development Program American Society of Clinical Oncology (ASCO), 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Achievement in Clinical Investigation Award M. D. Anderson Cancer Center Hematology-Oncology Fellowship Program, 2007
ASCO Young Investigator Award (YIA) - Redox Signaling in Multiple Myeloma American Society of Clinical Oncology (ASCO), 2006
Lymphoma Research Award, Runner-up Fellows Oncology Research Education Meeting (FOREM) - For Baseline Osteopenia and Osteoporosis in Untreated Non-Hodgkin's Lymphoma Patients, 2006
NCI Cancer Therapy Evaluation Program (CTEP) Externship, Bethesda, MD M. D. Anderson Cancer Center / NCI CTEP, 2006
ASH Clinical Research Training Institute (CRTI) American Society of Hematology (ASH) - For the proposed clinical trial "Phase I/II Study of Lenalidomide (Revlimid) in Multiple Myeloma Patients with Impaired Renal Function", 2006
Janice Davis Singletary Fellowship for Lymphoma M. D. Anderson Cancer Center, Lymphoma Department, 2006
AACR Scholarship, Molecular Biology in Clinical Oncology Workshop, Aspen, CO American Association of Cancer Research (AACR), 2005
Internal Medicine Resident Research Award Mayo Clinic College of Medicine, 2004
National ACP Research Poster Finalist American College of Physicians (ACP), 2003
Harry N. Hoffman II Humanitarian Student Clerkship Fund Award - Medical Volunteer in Nepal Mayo Medical School, 2000
Virginia Ott Kieckhefer Physician-Scientist Scholarship Mayo Medical School, 2000
Presidential Trainee Award American Society for Clinical Pharmacology (ASCPT), 2000
Hilldale Undergraduate/Faculty Research Scholarship UW-Madison, 1992
Join now to see all

Clinical Trials

Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels Start of enrollment: 2005 Jun 01
Completed
Not Applicable
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer Start of enrollment: 2006 Mar 14
Completed
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients Start of enrollment: 2005 Oct 01
Completed
Phase 1, Phase 2
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss Start of enrollment: 2006 Jan 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer
Htoo Zarni Oo, Zoltan Lohinai, Nastaran Khazamipour, Joey Lo, Gunjan Kumar
Cancers. 2021-09-06
1212 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20
45 citations
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, M...
Fay J. Hlubocky, Banu E. Symington, Daniel C. McFarland, Colleen M. Gallagher, Konstantin H. Dragnev
JCO Oncology Practice. 2021-02-08

Journal Articles

How can social media improve oncology care?
Thompson, MA, Community Oncology, 7/2013
Rabbit lung indolethylamine N-methyltransferase three–dimensional structure prediction: a model approach to bridge sequence to function in pharmacogenomic studies.
Thompson MA, Weinshilboum RM, El Yazal J, Wood TC, Pang Y-P, J Mol Model.
Denileukin diftitox activity in relapsed and refractory B-cell non-Hodgkin's lymphoma.
Thompson MA and Dang NH, Am J Oncol Rev
Practical Guidance: The Use of Social Media In Oncology Practice
Dizon DS, Graham D, Thompson MA, Johnson L, Johnston C, Fisch M, Miller R, Journal of Oncology Practice
Join now to see all

Lectures

ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with asses...
2019 ASCO Annual Meeting - 6/1/2019
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Oncology iPhone Applications: Perspectives From a Researcher/Community-Based Hematologist/Oncologist and a Physician Reviewer of Medical Apps.
Thompson MA and Misra S, Oncology. 2012; 26(3):1-2
http://www.cancernetwork.com/practice/content/article/10165/2044783
Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma
Li C, Thompson MA, Tamayo AT, Zuo Z, Li C, Lee J, Vega F, Ford RJ, Pham LV, Oncotarget
http://www.impactjournals.com/oncotarget
Indolethylamine N-Methyltransferase (INMT): Structural and Functional Studies
Thompson MA
Mayo Clinic

Press Mentions

Clinical Trial Mythbusters: Does the Clinical Trial Process Need an Extreme Makeover?July 9th, 2018
Session at ASCO Shows Community Oncology Success in Precision MedicineJune 3rd, 2018
What Is the State of Precision Medicine for Myeloma?March 15th, 2018

Committees

Member, ECOG-ACRIN Myeloma Core Committee 2009 - Present
Co-Chair, VIA Oncology Medical Oncology Lymphoma Committee 2015 - 2021
Member, ECOG-ACRIN NCORP Advisory Committee 2014 - 2021
Member, ASCO Cancer Education Committee on Lymphoma & Plasma Cell Disorders 2014 - 2017
CRF Council, ASCO Community Research Forum (CRF) Committee 2013 - 2022
Member, ASCO Cancer Research Committee (CRC) 2013 - 2016
Member, Conquer Cancer Foundation (CCF) Annual Giving Development Committee 2013 - 2014
Member, ASCO Integrated Media & Technology (IMT) / Education Committee 2010 - 2013

External Links

LinkedInhttp://www.linkedin.com/in/michaelthompsonmdphd
HealthTaphttps://www.healthtap.com/MikeThompsonMDPhD